Aviceda reports positive topline data for AVD-104 in patients with geographic atrophy

Aviceda Therapeutics announced positive safety and efficacy outcomes from part 1 of its phase 2/3 SIGLEC trial for AVD-104, which is being evaluated in patients with geographic atrophy secondary to age-related macular degeneration.
“We are excited to see signs of significant visual and functional improvement and rapid reduction in the rate of GA lesion growth with a positive overall safety profile following a single dose of AVD-104,” David Callanan, MD, chief medical officer and senior vice president at Aviceda, said in a company press release.
The two-part trial is investigating

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart